Healthcare Sales & Marketing Network News: Cardiome Pharma

Searching News Database: Cardiome Pharma

HSMN NewsFeed - 6 Jan 2021
Aethlon Medical Expands Leadership Team with Appointment of Chief Business Officer and Chief Medical Officer
Devices Personnel

HSMN NewsFeed - 3 Nov 2020
Aethlon Announces Appointment of Charles J. Fisher, Jr., M.D. as Chief Executive Officer
Devices Oncology Personnel

HSMN NewsFeed - 17 May 2018
Correvio Announces Enrollment of First Patient in Phase 3 Study Evaluating Brinavess(R) in China
Biopharmaceuticals Cardiology

HSMN NewsFeed - 30 Apr 2018
United Therapeutics To Acquire SteadyMed Ltd.
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 17 Apr 2018
Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess(R)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 12 Dec 2017
Cardiome Announces Strategic Licensing Agreement To Commercialize Aggrastat In Russia
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 29 Nov 2017
Aethlon Medical Names Dr. Charles J. Fisher Chairman of the Board
Devices Personnel

HSMN NewsFeed - 12 Sep 2017
Cardiome Announces Agreement with Basilea for Distribution of Zevtera(R)/Mabelio(R) (Ceftobiprole) in Europe and Israel
Biopharmaceuticals Licensing Distribution

HSMN NewsFeed - 21 Aug 2017
Cardiome Provides U.S. Regulatory Update For BRINAVESS
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 21 Jun 2017
Cardiome Announces Licensing Agreement for XYDALBA(TM) (Dalbavancin Hydrochloride) to Support Planned Commercialization in Israel
Biopharmaceuticals Licensing

HSMN NewsFeed - 12 Jun 2017
Cardiome Announces Commercial Launch of BRINAVESS(R) (Vernakalant Hydrochloride) in Canada
Biopharmaceuticals Cardiology Product Launch

HSMN NewsFeed - 31 Mar 2017
Novelion Therapeutics Appoints Mark Corrigan, M.D. to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Mar 2017
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in France
Biopharmaceuticals Product Launch

HSMN NewsFeed - 8 Dec 2016
Cardiome Announces Commercial Launch of Xydalba(TM) (dalbavancin) in the UK
Biopharmaceuticals Product Launch

HSMN NewsFeed - 29 Nov 2016
Cardiome Advances Toward the UK XYDALBA(TM) (dalbavancin) Launch
Biopharmaceuticals Reimbursement Product Launch

HSMN NewsFeed - 12 May 2016
Cardiome Announces the Launch of ESMOCARD Solution for Injection in France
Biopharmaceuticals Cardiology Product Launch

HSMN NewsFeed - 3 Mar 2016
Lumira Capital Announces Expansion of Investment Team with Appointment of Three Venture Partners
Devices Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 27 Oct 2015
CoLucid Pharmaceuticals Announces Election of Mark Corrigan, M.D., to Board of Directors
Biopharmaceuticals Neurology Personnel

HSMN NewsFeed - 7 Oct 2015
Quartet Medicine Completes $23.25 Million Series A Financing
Biopharmaceuticals Venture Capital Personnel

HSMN NewsFeed - 26 Sep 2012
Merck Returns Global Marketing and Development Rights for Vernakalant to Cardiome
Biopharmaceuticals Cardiology

HSMN NewsFeed - 20 Sep 2012
Cardiome Announces Appointment of Jennifer Archibald as Chief Financial Officer
Biopharmaceuticals Cardiology Personnel

HSMN NewsFeed - 24 Jul 2012
Oncothyreon Appoints Guy Cipriani as Vice President, Business Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 25 Jun 2010
Investigational BRINAVESS (vernakalant) for Infusion Recommended for Approval by the CHMP in the European Union (EU) for the Rapid Conversion of Recent Onset Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 14 May 2010
Merck and Cardiome Announce Phase III Study Results Comparing Investigational Compound BRINAVESS(TM) (Vernakalant) Intravenous to Amiodarone Injection in Conversion of Atrial Fibrillation to Normal Sinus Rhythm
Biopharmaceuticals Cardiology

HSMN NewsFeed - 26 Aug 2009
Marketing Application for Vernakalant Intravenous (IV) Filed in Europe for the Treatment of Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 19 May 2009
Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 11 Aug 2008
Cardiome And Astellas Announce Receipt Of FDA Approvable Letter For KYNAPID(TM)
Biopharmaceuticals FDA Cardiology

HSMN NewsFeed - 2 Jul 2008
Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing
Devices Acquisitions

HSMN NewsFeed - 25 Mar 2008
Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Biopharmaceuticals Cardiology

HSMN NewsFeed - 21 Jan 2008
Cardiome And Astellas Announce Regulatory Update
Biopharmaceuticals FDA

HSMN NewsFeed - 11 Dec 2007
FDA Advisory Committee Recommends Approval of KYNAPID(TM) for Acute Atrial Fibrillation
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 30 Apr 2007
Cardiome Announces In-Licensing Agreement With Eli Lilly and Company
Biopharmaceuticals Licensing

HSMN NewsFeed - 27 Mar 2007
Cardiome Announces Appointment of Chairman
Biopharmaceuticals Personnel

HSMN NewsFeed - 22 Feb 2007
Cardiome Announces Management Appointments
Biopharmaceuticals Cardiology Personnel

HSMN NewsFeed - 4 Dec 2006
New Atlanta-Based Pharmaceutical Company Focuses on Central Nervous System
Biopharmaceuticals Neurology

HSMN NewsFeed - 27 Sep 2006
Cardiome Announces USAN Name And Patent Grant
Biopharmaceuticals Cardiology

HSMN NewsFeed - 31 May 2006
Cardiome Announces Refusal To File Decision By The FDA
Biopharmaceuticals Cardiology FDA

Return to NewsFeed

Additional items found! 16

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 16 additional stories matching:
Cardiome Pharma
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.